Celltrion Healthcare was awarded US$300 Million Export Tower Prize at the 52nd Trade Day Commemoration Ceremony on Dec. 7. Mr. Hong Seung-seo, president and CEO of the company, was awarded the Silver Tower Order of Industrial Service Merit for his role in the company’s achievement of a three-year-average export growth rate of 1,492 percent.
The US$300 Million Export Tower Prize is to commemorate the successful export of the Remsima, the world’s first antibody biosimilar that is developed by Celltrion. The prize is unprecedented in the domestic pharmaceutical industry. So far, Yuhan Corporation, Green Cross and Celltrion won the US$100 Million Export Tower Prize in 2013, 2014 and 2008, respectively.
Celltrion Healthcare is the company in charge of global distribution and marketing of biopharmaceuticals produced by Celltrion. The company recorded approximately US$263 million in exports in the first half of this year. It is when the export of Remsima to Europe started in earnest to result in a year-on-year export growth of 250 percent or so. At present, Celltrion Healthcare is engaged in marketing the product in 63 countries around the world, including Europe, Canada, Brazil and Australia.